Key result
Higher normalized furosemide dose was an independent predictor of all-cause mortality in clinically stable outpatients with chronic heart failure (P=0.017).
Why the study?
Does higher orally administered furosemide dose predict all-cause mortality in outpatients with chronic HF and LVEF ≤ 45%?
Population
400 outpatients with chronic heart failure (HF) and left ventricular ejection fraction (EF) ≤ 45%
Design
Cohort
Follow-up
median 32 months
Authors
Loading...
Higher furosemide doses should not yet change practice in stable HF outpatients; leaves open whether dose reduction improves survival.
Cohort (n=400)
Does higher orally administered furosemide dose predict all-cause mortality in outpatients with chronic HF and LVEF ≤ 45%?
p-value: p=0.017
Higher normalized furosemide doses are associated with increased all-cause mortality in clinically stable outpatients with chronic systolic heart failure, suggesting potential harm of high doses in the absence of congestion.
Dini et al. (2011) conducted a cohort in chronic systolic heart failure (n=400). furosemide was evaluated on all cause-mortality (p=0.017). Higher normalized furosemide dose was an independent predictor of all-cause mortality in clinically stable outpatients with chronic heart failure (P=0.017).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: